Detalles de la búsqueda
1.
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
J Pharmacol Exp Ther
; 367(2): 245-251, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30150483
2.
Molnupiravir: Mechanism of action, clinical, and translational science.
Clin Transl Sci
; 17(2): e13732, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38593352
3.
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.
Clin Pharmacol Ther
; 113(6): 1337-1345, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017631
4.
Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
Clin Transl Sci
; 16(10): 1947-1956, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37526305
5.
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults.
Biomed Pharmacother
; 169: 115851, 2023 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37976891
6.
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
CPT Pharmacometrics Syst Pharmacol
; 12(12): 1859-1871, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37798914
7.
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.
Clin Transl Sci
; 15(7): 1753-1763, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35506164
8.
A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
Clin Transl Sci
; 15(11): 2697-2708, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36053806
9.
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Clin Pharmacol Drug Dev
; 10(5): 556-566, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125189
10.
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
EBioMedicine
; 73: 103651, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34775220
11.
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Antivir Ther
; 24(1): 45-50, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30375984
12.
A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species.
MAbs
; 10(8): 1322-1331, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30130450
13.
Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA.
J Clin Pharmacol
; 58(7): 885-890, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29663424
14.
Bone Mineral Density to Assess Pediatric Bone Health in Drug Development.
Ther Innov Regul Sci
; 51(6): 756-760, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30227097
15.
Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.
PLoS One
; 11(12): e0168709, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-28036343
Resultados
1 -
15
de 15
1
Próxima >
>>